Veracyte - VCYT Stock Forecast, Price & News

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Analyst Ratings Changes

Several equities analysts recently weighed in on VCYT shares. Needham & Company LLC raised their target price on shares of Veracyte from $26.00 to $31.00 and gave the company a "buy" rating in a research note on Wednesday, August 3rd. Raymond James raised their price target on Veracyte from $30.00 to $31.00 and gave the company an "outperform" rating in a report on Thursday, August 4th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $42.50.

Veracyte Price Performance

Veracyte stock traded down $2.70 during mid-day trading on Tuesday, hitting $24.13. 916,558 shares of the company's stock traded hands, compared to its average volume of 953,496. Veracyte has a fifty-two week low of $14.85 and a fifty-two week high of $54.13. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -35.48 and a beta of 1.10. The firm has a 50 day simple moving average of $22.27 and a two-hundred day simple moving average of $23.76.

Insider Transactions at Veracyte

In other news, Director Jens Holstein sold 8,720 shares of Veracyte stock in a transaction on Tuesday, June 14th. The stock was sold at an average price of $16.27, for a total transaction of $141,874.40. Following the completion of the sale, the director now owns 2,000 shares of the company's stock, valued at $32,540. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Marc Stapley bought 60,000 shares of the company's stock in a transaction dated Friday, June 10th. The stock was bought at an average price of $16.33 per share, with a total value of $979,800.00. Following the completion of the acquisition, the chief executive officer now owns 159,761 shares of the company's stock, valued at $2,608,897.13. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jens Holstein sold 8,720 shares of Veracyte stock in a transaction on Tuesday, June 14th. The stock was sold at an average price of $16.27, for a total value of $141,874.40. Following the sale, the director now directly owns 2,000 shares of the company's stock, valued at approximately $32,540. The disclosure for this sale can be found here. Insiders own 2.90% of the company's stock.